Paragon Bioservices Launches Second Expansion to Celebrate its 20th Anniversary

BALTIMORE, Oct. 27 /PRNewswire/ -- Paragon Bioservices, a Baltimore-based CMO focused on the contract research, process development and manufacturing of biologics, announced today that the company will celebrate its 20th anniversary in November by undergoing a second expansion of facilities at the University of Maryland Biopark in Baltimore, MD. The expansion will double existing GMP manufacturing capacity, include additional research and process development laboratories and add fill and finish capabilities. Completion is scheduled for the second quarter of 2011.

When completed, the "New Paragon," approximately a 45,000 square foot facility, will be the only multiple project GMP contract manufacturing organization (CMO) in the Baltimore-Metropolitan area and only one of a few in the Mid-Atlantic region.

Marco Chacon, Ph.D., CEO of Paragon Bioservices, commented, "As the demand for the development of biopharmaceuticals continues to increase, Paragon is meeting our customer demands with expansions to our facilities, staff and equipment. This enhances our ability to produce recombinant proteins, both for research purposes and for Phase I and II clinical trials."

About Paragon Bioservices

Paragon Bioservices is a contract research and manufacturing organization (CMO) that provides a comprehensive portfolio of services -- including process development, GMP manufacturing and cell banking. Paragon's focus is to bridge the translational divide, to enable protein and cell-based therapeutics into clinical trials. Our experienced process engineers, regulatory compliance associates and project managers work with our clients -- from start to finish. For more information about Paragon Bioservices, please visit www.paragonbioservices.com.

Media Contacts:

Tiberend Strategic Advisors, Inc.

(212) 827-0020


Tamara Bright

tbright@tiberendstrategicadvisors.com

or

Claire Sojda

csojda@tiberendstrategicadvisors.com



SOURCE Paragon Bioservices

Back to news